What do systematic reviews say?

741 questions · 808 findings · 27 reviews · Oral medicine and oral cancer · related questions CL0289

Sort:Best matchNewestHighest certainty Download CSV

No studies found 95 · 11.8%GRADE not reported 498 · 61.6%Very low 134 · 16.6%Low 53 · 6.6%Moderate 27 · 3.3%High 1 · 0.1%

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Empirical antifungal treatment · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs absorbed from GI tract showed no clear difference in empirical antifungal treatment compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.89 [0.68, 1.16]
4 studies · 1031 participants
GRADE not reported

Norfloxacin plus amphotericin B vs Amphotericin B

Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy

Norfloxacin plus amphotericin B showed no clear difference in systemic fungal infection compared with amphotericin B; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.67 [0.2, 2.23]
1 study · 106 participants
GRADE not reported

Antifungal drugs partially absorbed from GI tract (miconazole, clotrimazole) vs placebo or no treatment

Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs partially absorbed from GI tract (miconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.16 [0.06, 0.46]
4 studies · 292 participants
GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Amount of analgesia · Patients with cancer receiving chemotherapy and/or radiotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
No trial reported this planned secondary outcome for any comparison in this review
Studies not reported
No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs absorbed from GI tract showed no clear difference in systemic fungal infection compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.59 [0.33, 1.06]
8 studies · 2103 participants
GRADE not reported

Itraconazole vs Fluconazole

Death associated with fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy

Itraconazole showed no clear difference in death associated with fungal infection compared with fluconazole; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.14 [0.01, 2.73]
1 study · 202 participants
GRADE not reported

Antifungal drugs partially absorbed from GI tract (miconazole, clotrimazole) vs placebo or no treatment

Empirical antifungal treatment · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in empirical antifungal treatment compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 3.38 [0.15, 77.12]
1 study · 32 participants
GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Death associated with fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs absorbed from GI tract showed no clear difference in death associated with fungal infection compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 1.25 [0.38, 4.13]
3 studies · 981 participants
GRADE not reported

Nystatin vs Chlorhexidine plus nystatin

Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy

Nystatin showed no clear difference in oral candidiasis (present) compared with chlorhexidine plus nystatin; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 1.82 [0.73, 4.54]
1 study · 50 participants
GRADE not reported

Antifungal drugs not absorbed from GI tract vs placebo or no treatment

Death associated with fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs not absorbed from GI tract showed no clear difference in death associated with fungal infection compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.16 [0.01, 2.95]
1 study · 51 participants
GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Relief of pain · Patients with cancer receiving chemotherapy and/or radiotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
No trial reported this planned secondary outcome for any comparison in this review
Studies not reported
No studies found

Nystatin vs placebo or no treatment

Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy

Nystatin showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.92 [0.78, 1.08]
3 studies · 153 participants
GRADE not reported

Nystatin vs Natamycin

Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy

Nystatin showed no clear difference in oral candidiasis (present) compared with natamycin; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 1.07 [0.83, 1.37]
1 study · 28 participants
GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs absorbed from GI tract led to lower oral candidiasis (present) compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.4 [0.21, 0.76]
8 studies · 2103 participants
GRADE not reported

Antifungal drugs not absorbed from GI tract vs placebo or no treatment

Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs not absorbed from GI tract showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.1 [0.01, 1.75]
2 studies · 71 participants
GRADE not reported

Ketoconazole vs Itraconazole

Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
1 study (Caselli 1990); no evidence of a difference; not estimable/not pooled
1 study
GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
RR 0.47 [0.29, 0.78]
7 studies · 1153 participants
GRADE not reported

Tongue scraping (mechanical tongue cleaning) vs Placebo or no intervention (nothing)

Outcome not reported · Adults (over 18 years) with a clinical or self-assessed diagnosis of halitosis

The review found no eligible studies for this question.

1 finding from 1 review

Tongue scraping for treating halitosis 2006 · Cochrane All outcomes
Minimum 4 weeks (planned)
No eligible randomized controlled trials comparing tongue scraping with placebo or no intervention were identified.
0 studies
No studies found

Tongue scraper or tongue cleaner (One Drop Only tongue cleaner; Tongue-Putzer scraper; polystyrene scraper) vs Toothbrush (used to clean the tongue)

Volatile sulphur compounds (VSC), halimeter · Adults (over 18 years) with a clinical or self-assessed diagnosis of halitosis

1 finding from 1 review

Tongue scraping for treating halitosis 2006 · Cochrane All outcomes
Immediately to 35 min post-intervention (Seemann 2001); 1 week (Pedrazzi 2004)
No summary of findings table or GRADE assessment (pre-GRADE review); narrative synthesis, data not pooled. Seemann 2001: peak VSC reduction 42% with the tongue cleaner, 40% with the tongue scraper and 33% with the…
2 studies · 40 participants
GRADE not reported

Tongue scraper or tongue cleaner (One Drop Only tongue cleaner; Tongue-Putzer scraper; polystyrene scraper) vs Toothbrush (used to clean the tongue)

Self-expressed (perceived) or organoleptic (human nose) assessment of halitosis · Adults (over 18 years) with a clinical or self-assessed diagnosis of halitosis

The review found no eligible studies for this question.

1 finding from 1 review

Tongue scraping for treating halitosis 2006 · Cochrane All outcomes
Minimum 4 weeks (planned)
Neither of the two included trials provided any self expressed (perceived) or organoleptic (human nose) assessments of halitosis (the review's primary outcomes); no data.
0 studies
No studies found